These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 6766207)

  • 1. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens.
    Reddy JK; Azarnoff DL; Hignite CE
    Nature; 1980 Jan; 283(5745):397-8. PubMed ID: 6766207
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate.
    Reddy JK; Krishnakantha TP
    Science; 1975 Nov; 190(4216):787-9. PubMed ID: 1198095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver.
    Reddy JK; Rao MS; Azarnoff DL; Sell S
    Cancer Res; 1979 Jan; 39(1):152-61. PubMed ID: 83907
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatocarcinogenesis of peroxisome proliferators.
    Rao MS; Reddy JK
    Ann N Y Acad Sci; 1996 Dec; 804():573-87. PubMed ID: 8993574
    [No Abstract]   [Full Text] [Related]  

  • 5. Properties of hypolipidemic peroxisome proliferators in the lymphocyte [3H]thymidine and Salmonella mutagenesis assays.
    Warren JR; Simmon VF; Reddy JK
    Cancer Res; 1980 Jan; 40(1):36-41. PubMed ID: 6765917
    [No Abstract]   [Full Text] [Related]  

  • 6. Peroxisome proliferation and hepatotoxicity in rodents.
    Grasso P
    Biochem Soc Trans; 1985 Oct; 13(5):861-2. PubMed ID: 4065422
    [No Abstract]   [Full Text] [Related]  

  • 7. Excessive accumulation of autofluorescent lipofuscin in the liver during hepatocarcinogenesis by methyl clofenapate and other hypolipidemic peroxisome proliferators.
    Reddy JK; Lalwani ND; Reddy MK; Qureshi SA
    Cancer Res; 1982 Jan; 42(1):259-66. PubMed ID: 7053853
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term effects of hypolipidemic peroxisome proliferator administration on hepatic hydrogen peroxide metabolism in rats.
    Tamura H; Iida T; Watanabe T; Suga T
    Carcinogenesis; 1990 Mar; 11(3):445-50. PubMed ID: 2311188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of peroxisome proliferator-induced hepatocarcinogenesis.
    Rao MS; Reddy JK
    Environ Health Perspect; 1991 Jun; 93():205-9. PubMed ID: 1685443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643.
    Reddy JK; Azarnoff DL; Sirtori CR
    Arch Int Pharmacodyn Ther; 1978 Jul; 234(1):4-14. PubMed ID: 708142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
    Rao MS; Dwivedi RS; Subbarao V; Reddy JK
    Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of chemically induced hyperplasia in the carcinogenic activity of the hypolipidemic carcinogens.
    Butterworth BE; Loury DJ; Smith-Oliver T; Cattley RC
    Toxicol Ind Health; 1987 Jun; 3(2):129-49. PubMed ID: 3303446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643.
    Peters JM; Cattley RC; Gonzalez FJ
    Carcinogenesis; 1997 Nov; 18(11):2029-33. PubMed ID: 9395198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of hepatic ornithine decarboxylase by hypolipidemic drugs with hepatic peroxisome proliferative activity.
    Izumi K; Reddy JK; Oyasu R
    Carcinogenesis; 1981; 2(7):623-7. PubMed ID: 7273341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phthalate esters as peroxisome proliferator carcinogens.
    Warren JR; Lalwani ND; Reddy JK
    Environ Health Perspect; 1982 Nov; 45():35-40. PubMed ID: 6754363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of rodent liver carcinogenesis.
    Michalopoulos GK; Eckl PM; Cruise JL; Novicki DL; Jirtle RL
    Toxicol Ind Health; 1987 Jun; 3(2):119-28. PubMed ID: 3303445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of a 65-kDa tumor-associated protein in altered hepatic foci of rats fed the peroxisome proliferator Wy-14,643.
    Hanausek M; Sherman U; Mirowski M; Adams AK; Walaszek Z
    Prog Clin Biol Res; 1994; 387():337-48. PubMed ID: 7972257
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of hepatocellular carcinomas and increased peroxisomal fatty acid beta-oxidation in rats fed [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) in the semipurified diet.
    Lalwani ND; Reddy MK; Qureshi SA; Reddy JK
    Carcinogenesis; 1981; 2(7):645-50. PubMed ID: 7273344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the hepatic effects of nafenopin and WY-14,643 on peroxisome proliferation and cell replication in the rat and Syrian hamster.
    Lake BG; Evans JG; Cunninghame ME; Price RJ
    Environ Health Perspect; 1993 Dec; 101 Suppl 5(Suppl 5):241-7. PubMed ID: 8013414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens.
    Williams GM; Perrone C
    Ann N Y Acad Sci; 1996 Dec; 804():554-72. PubMed ID: 8993573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.